A Comprehensive Approach to Cough Hypersensitivity
Unlike other therapies being developed to treat chronic cough, Haduvio takes a broader approach to cough management by acting both centrally and peripherally in the nervous system. Haduvio acts as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity, which is thought to be the link across various chronic cough disorders.
Haduvio’s Differentiated Central and Peripheral Mechanism of Action (MOA)
Haduvio has a novel approach to controlling cough through its KAMA mechanism. By targeting these receptors along the cough reflex arc, it has the potential to work independent of the initial cough trigger.
Due to its KAMA mechanism, we believe Haduvio is well suited to address chronic cough across a variety of conditions.
For more information on our global clinical development programs, please visit our Pipeline page.